Mineralys Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	217.6	114.09	49.3	87.7	10.61	1.41
Short-Term Investments	376.03	84.1	187.26	22.41	-	-
Cash & Short-Term Investments	593.63	198.19	236.57	110.11	10.61	1.41
Cash Growth	125.20%	-16.22%	114.85%	937.60%	653.16%	-
Prepaid Expenses	6.17	7.16	12.54	2.7	0.46	0.06
Restricted Cash	-	-	-	-	0.05	-
Total Current Assets	599.8	205.35	249.1	112.81	11.12	1.47
Property, Plant & Equipment	0.01	0.05	-	-	-	-
Long-Term Investments	-	-	2.48	-	-	-
Long-Term Deferred Charges	-	0.4	-	1.6	0	-
Other Long-Term Assets	0.14	0.1	0.05	0.03	-	0.02
Total Assets	599.95	205.9	251.64	114.44	11.13	1.49
Accounts Payable	1.12	0.48	0.6	1.91	0.76	0.53
Accrued Expenses	22.4	14.17	9.88	6.16	4.29	0.05
Short-Term Debt	-	-	-	-	-	4.5
Total Current Liabilities	23.52	14.65	10.48	8.07	5.05	5.08
Total Liabilities	23.52	14.65	10.48	8.07	5.05	5.08
Common Stock	0.01	0.01	0	0	0	0.01
Additional Paid-In Capital	1,001	493.77	365.86	0.54	0.09	-
Retained Earnings	-424.94	-302.52	-124.71	-52.81	-23.01	-3.6
Total Common Equity	576.43	191.26	241.15	-52.27	-22.93	-3.6
Shareholders' Equity	576.43	191.26	241.15	106.38	6.07	-3.6
Total Liabilities & Equity	599.95	205.9	251.64	114.44	11.13	1.49
Total Debt	-	-	-	-	-	4.5
Net Cash (Debt)	593.63	198.19	236.57	110.11	10.61	-3.09
Net Cash Growth	125.20%	-16.22%	114.85%	937.60%	-	-
Net Cash Per Share	9.92	4.08	6.54	21.31	2.13	-0.67
Filing Date Shares Outstanding	79.14	49.84	49.63	40.86	5.44	4.63
Total Common Shares Outstanding	78.97	49.82	41.13	6.42	5.44	4.63
Working Capital	576.28	190.71	238.62	104.74	6.07	-3.62
Book Value Per Share	7.30	3.84	5.86	-8.14	-4.21	-0.78
Tangible Book Value	576.43	191.26	241.15	-52.27	-22.93	-3.6
Tangible Book Value Per Share	7.30	3.84	5.86	-8.14	-4.21	-0.78

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q